Business Context and Reporting Period
Company: China Pharma Holdings, Inc. (CPHI)
Filing Type: Form 8-K (Current Report)
Date of Report: February 5, 2026
Reporting Period: Event date February 5, 2026; Closing expected by February 20, 2026.
The Company, through its wholly owned subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd., entered into a Material Definitive Agreement to acquire intellectual property rights.
Key Financial Metrics and Transaction Details
This filing reports a specific transaction rather than periodic financial performance. Key metrics related to the transaction include:
- Transaction Value: $8.82 million.
- Payment Method: Issuance of common stock (no cash outflow).
- Share Issuance: 12,600,000 restricted shares of common stock.
- Implied Share Price: $0.70 per share.
- Asset Acquired: Invention patent for "Topiroxostat Nanoemulsion and Method for Its Preparation."
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes
The primary material change is the entry into a Technology Transfer Agreement with Xiaoyun Chen. This agreement involves the transfer of ownership of the Invention Patent to the Company's subsidiary. Additionally, the Company will issue 12,600,000 unregistered shares of common stock to the Transferor as consideration.
Outlook, Risks, and Contingencies
- Technical Services: The Transferor or a designated third party is obligated to provide technical services, including product R&D, writing registration materials, and registration applications.
- Closing Contingency: The transaction is expected to close by February 20, 2026.
- Regulatory Status: The securities are being issued in reliance on the exemption from registration under Regulation S, as the transaction is an offshore transaction with a non-U.S. person.
- Confidentiality: Portions of the agreement exhibit have been omitted due to confidential information.
Investor Verification Checklist
- Verify the closing of the transaction by the expected date of February 20, 2026.
- Confirm the issuance of 12,600,000 restricted shares and the resulting dilution impact on existing shareholders.
- Review the full Technology Transfer Agreement (Exhibit 10.1) once available to assess specific milestones for technical services and patent registration.
- Monitor the regulatory status of the Topiroxostat Nanoemulsion product development.